← Back to front page
United States · Financial press · Investor's Business Daily

Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug

Published by Investor's Business Daily · United States 11 min ago
Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug
Investor's Business Daily

Detailed summary

Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab. The post Summit Crumbles After FDA…

Summit Therapeutics (SMMT) stock crashed Monday after the Food and Drug Administration rejected its Merck (MRK)-rivaling lung cancer drug, ivonescimab. Leerink Partners analyst Daina Graybosch wasn't surprised, noting the FDA said ivonescimab in combination with chemotherapy would need to improve overall survival to win approval. Overall survival is how long patients live before dying of any cause. The regimen failed…

Opening of the article, excerpted from Investor's Business Daily. To read the rest, open the article on the publisher's site.

Read the full article on Investor's Business Daily Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)

Also worth reading